Top news of the week: 11.08.2020.
Biotechnology, Therapy, Medicine, Dot-com bubble, Acute respiratory distress syndrome, Vaccination
Startups
RT @FierceBiotech: That $10.7 billion was driven by a couple of outsize deals and includes $1.4 billion raised in five IPOs, $1.6 billion in follow-on offerings and $3 billion in venture capital. https://t.co/EQK7N6rnBF
OpenIn the face of COVID-19, cell and gene therapy space shows ‘remarkable resilience:’ report
In the early days of COVID-19, the Alliance for Regenerative Medicine was unsure how the pandemic and its accompanying economic downturn would affect the cell and gene therapy space. Now, ...
RT @IAmBiotech: The BIOEquality agenda “will challenge our companies, the government, and yes, even ourselves, to make ‘diversity’ more than just a word or a program but a part of who we are and what we stand for,” says @DrMichelleBIO in @BioCentury https://t.co/0zrZstzwNB
OpenBIO challenging its members to walk the talk on social justice
Outrage over the killing of George Floyd prompted biopharma leaders and companies to look up from their work developing molecules to consider their companies’ roles in advancing social ...
“Drug startups, which often have no revenue, are most vulnerable if investors decide biotech isn’t worth the risk”
@LabCentral’s @JFruehauf weighs in on how the administration’s new drug-pricing exec orders could impact the biotech industry in @WSJ. Link: https://t.co/btEfIZw2fI
OpenVenture Capitalists Push Back on Trump Drug-Pricing Measure
Pegging certain Medicare drug prices to those in other countries would thwart innovation, some investors claim.
Welcome to GV. Taysha Gene Therapies develops curative medicines for neurodegenerative diseases, neurodevelopmental disorders, and genetic forms of epilepsy – https://t.co/scYXUtxQiq
OpenTaysha raises $95M to take 4 CNS gene therapies into the clinic
Taysha Gene Therapies has raised $95 million to take four gene therapies into humans. The series B, which comes months after Taysha’s $30 million seed round, positions ex-AveXis executives ...
Venture capital is still soaring, but the business is changing https://t.co/VUYTeAGTJs #VC #startups #Entrepreneurship
OpenVenture capital is still soaring, but the business is changing
The pandemic is changing some crucial things about how venture capitalists invest — and how startups use that money to hire — that could affect Massachusetts in worrisome ways.
Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More
The novel coronavirus has driven the pharmaceutical industry to upend its research priorities. Big Pharma companies are focusing on vaccine development
“You can see there was no difference between the responses in 5 and 25 mcg. In other words, this is a dose sparing regimen,” Novavax R&D chief Gregory Glenn, M.D., said https://t.co/D7SWrrOh7R
OpenNovavax’s COVID-19 vaccine looks promising in early data
A month after scoring $1.6 billion from the U.S. government, Novavax is posting the first human data from its COVID-19 vaccine. The early data, from the phase 1 part of a phase 1/2 study, ...
Japan says in deal to purchase AstraZeneca's COVID-19 vaccine https://t.co/LrNxvYmKJg https://t.co/Q2RRdEVyOZ
OpenJapan in deals with AstraZeneca, Novavax for COVID-19 vaccines
Japan plans to buy AstraZeneca Plc's experimental COVID-19 vaccine and fund a local company to manufacture Novavax's vaccine candidate, ramping up its stockpile plan as it battles surging ...